GlassScriptPhysician profile
Syed N Babar
NPI 1841513975
$8,028.62
in general payments reported to CMS, 2019-2025
34 companies · $662 in 2025
The $662 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,287 · 2020: $869 · 2021: $1,092 · 2022: $1,239 · 2023: $1,302 · 2024: $576 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,540.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk As | $1,414.23 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $763.58 | 2019-2023 | Lokelma, Farxiga |
| Amgen INC. | $689.15 | 2019-2025 | Tavneos, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $635.27 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $443.77 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $415.29 | 2019-2025 | Veltassa |
| Mallinckrodt Hospital Products INC. | $388.24 | 2020-2025 | Terlivaz |
| Aurinia Pharma U.S., INC. | $318.90 | 2021-2024 | Lupkynis |
| Travere Therapeutics, INC. | $292.19 | 2019-2025 | |
| Horizon Therapeutics Plc | $290.57 | 2019-2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $258.62 | 2019-2024 | Velphoro, Korsuva |
| Glaxosmithkline, LLC. | $249.76 | 2020-2024 | Jesduvroq, Benlysta |
| Novartis Pharmaceuticals Corporation | $221.59 | 2019-2025 | |
| Daiichi Sankyo INC. | $215.08 | 2019-2023 | Injectafer |
| Opko Pharmaceuticals, LLC | $195.52 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $142.25 | 2019 | |
| Calliditas Therapeutics US INC. | $137.54 | 2023-2025 | Tarpeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $137.39 | 2020-2024 | Gattex |
| Alexion Pharmaceuticals, INC. | $119.66 | 2019-2024 | Ultomiris |
| Akebia Therapeutics INC | $117.40 | 2020-2025 | Vafseo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.66 | 2023-2025 | Jardiance |
| Philips North America LLC | $93.87 | 2020 | |
| Mallinckrodt Enterprises LLC | $72.55 | 2019 | |
| Novo Nordisk INC | $64.38 | 2024-2025 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $50.23 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Bard Peripheral Vascular, INC. | $42.29 | 2023-2024 | Glidepath, Pristine |
| Ultragenyx Pharmaceutical INC. | $33.77 | 2021-2023 | |
| Lilly USA, LLC | $30.27 | 2025 | Jardiance |
| Shire North American Group INC | $28.88 | 2019 | |
| Cormedix INC. | $26.47 | 2025 | Defencath |
| Ani Pharmaceuticals, INC. | $18.28 | 2025 | Purified Cortrophin Gel |
| Astellas Pharma US INC | $17.97 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Babar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.